0.4250GBp0.00%Mkt Cap: 6.43M GBpP/E: —Last update: 2026-06-01
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transp…
Industry Peers
Diagnostics & Research183.26BUSDP/E 27.1
127.46BUSDP/E 35.0
45.09BUSDP/E 42.1
38.48BUSDP/E 27.4
37.00BUSDP/E 47.9
34.66BCHFP/E 38.1
31.51BUSD—
31.45BUSDP/E 23.4
Indicators:|
Key Statistics
Company
Market Cap6.43M GBp
Enterprise Value845.80K GBp
Revenue (TTM)1.91M GBp
Gross Profit1.56M GBp
Net Income (TTM)-5.87M GBp
Revenue/Share0.0080 GBp
Last Price0.4250 GBp
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees15
CountryGB
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.12
EV/Revenue0.44
P/S3.36
P/B0.56
EPS (TTM)-0.02
EPS (Forward)0.00
52W Range
0.40002% of range1.750
52W High1.750 GBp
52W Low0.4000 GBp
Profitability
Gross Margin81.60%
Oper. Margin-162.05%
EBITDA Margin0.00%
Profit Margin-175.92%
ROE-111.57%
ROA-78.40%
Growth
Revenue Growth-42.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.02M GBp
CapEx (TTM)193.00K GBp
FCF Margin-188.45%
FCF Yield-56.05%
Net Debt-185.00K GBp
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity0.07
Current Ratio0.91
Quick Ratio0.68
Book Value/Sh0.0076 GBp
Cash/Share0.0020 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.900 GBp
Target Range2.900 GBp – 2.900 GBp
# Analysts1
Ownership
Shares Out.1.51B
Float171.92M
Insiders3.86%
Institutions68.85%
Technical
SMA 500.4817 (-11.8%)
SMA 2000.6390 (-33.5%)
Beta1.30
S&P 52W Chg27.94%
Avg Vol (30d)980.55K
Avg Vol (10d)865.00K
Technical Indicators
RSI (14)14.3
MACD-0.0216
MACD Signal-0.0214
MACD Hist.-0.0003
BB Upper0.4995 GBp
BB Middle0.4502 GBp
BB Lower0.4010 GBp
BB Width21.88%
ATR (14)0.0536 GBp
Vol Ratio (20d)0.85x